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ABSTRACT: Ultrasound-guided core biopsy provides many benefits
compared with fine-needle aspiration cytology and has begun to emerge
as part of the diagnostic work-up for a salivary gland lesion. Although
the increased potential for tumor-seeding and capsule rupture has been
extensively discussed, the safety of this procedure is widely accepted
based on infrequent reports of tumor-seeding. In fact, a review of the
literature shows only 2 cases of salivary tumor seeding following biopsy
with larger-gauge needle characteristics, with 2 reported cases of
salivary tumor seeding following fine-needle aspiration cytology.
However, the follow-up interval of such studies (<7 years) is
substantially less than the 20-year follow-up typically necessary to
detect remote recurrence. Studies on tumor recurrence of pleomorphic
adenoma, the most common salivary gland lesion, suggest that as many
as 16% of tumor recurrences occur at least 10 years following initial
surgery, with average time to recurrence ranging anywhere from 6.1 to
11.8 years postoperatively. Despite the benefits of ultrasound-guided
core biopsy over fine-needle aspiration biopsy, which include both
improved consistency and diagnostic accuracy, current studies lack
adequate patient numbers and follow-up duration to confirm comparable
safety profile to currently accepted fine-needle aspiration cytology. In
this report we: (1) compare the relative benefits of each procedure, (2)
review evidence regarding tumor seeding in each procedure, (3) discuss
time course and patient numbers necessary to detect tumor recurrence,
and (4) describe how these uncertainties should be factored into clinical
considerations. VC 2012 Wiley Periodicals, Inc. Head Neck 35:
1657–1661, 2013
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INTRODUCTION
Ultrasound-guided core biopsy offers quantifiable benefits
in the assessment of salivary gland tumors compared with
the long-accepted standard, fine-needle aspiration cytol-
ogy, specifically the following: improved sensitivity and
specificity, decreased inadequacy rate, and increased con-
sistency.5,6 These benefits must be weighed against the
potential for increased complication risks including: (1)
hemorrhage, (2) facial nerve injury, and (3) tumor-seed-
ing. Although such risks intuitively increase with the
more invasive, larger-diameter ultrasound-guided core bi-
opsy procedure, quantifying relatively infrequent compli-
cations through formal analysis has proven difficult, in
part, because of the large population numbers and long
follow-up duration necessary. In fact, initial studies have
reported a relatively similar clinical safety profile
between these 2 techniques. Based on initial studies,
which reported no cases of tumor seeding following core-
biopsy of 438 lesions followed for 7 years,1 and limited
case reports of tumor-seeding,7,8 the safety of ultrasound-
guided core biopsy has become widely accepted.9 This
widespread adoption of ultrasound-guided core biopsy
remains concerning because published reports lack the
statistical power and follow-up necessary to detect tumor-
seeding. We review the advantages of each technique,
highlight existing clinical and basic science evidence
regarding the potential risk for recurrence with each tech-
nique, detail the expected time course for recurrence of
salivary gland tumors, and discuss how this should focus
future scientific inquiry and clinical decision making.
Background
Biopsy informs clinical decision making regarding
management of parotid-gland lesions. After initial imag-
ing (usually via ultrasound or MRI), a biopsy can distin-
guish between neoplastic lesions (which are usually man-
aged surgically) and non-neoplastic lesions (which are
usually managed conservatively). Furthermore, biopsy can
potentially distinguish between benign and malignant neo-
plasms, which guides the extent of the surgical dissection.
Open, cervical node biopsy prior to definitive treatment
was shown to increase rates of local cervical recurrence
and distant metastasis, as well as decrease survival rate10
compared with patients who had no biopsy or biopsy only
at the time of definitive treatment. These findings ended
the routine use of open biopsy for salivary gland tumors
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and focused on preoperative diagnostic techniques, which
also minimized the potential for tumor-seeding and cap-
sule rupture.
Whereas preoperative diagnostics are not essential to
the management of all salivary gland lesions, because
resection with intraoperative frozen sections remains a
reasonable alternative, diagnostic procedures such as fine-
needle aspiration cytology and ultrasound-guided core bi-
opsy allow improved counseling and operative planning
in the setting of malignant tumors. Fine-needle aspiration
cytology emerged as the initial diagnostic procedure of
choice. Although the potential for tumor seeding has been
shown to vary greatly based on the type of tumor and
anatomic site, analysis of 11,700 abdominal biopsies per-
formed with fine needles (defined as 20-, 21-, 22-, and
23-gauge) demonstrated sufficiently low rates of tumor
seeding (0.017%) to justify preoperative utility.11 A study
limited to biopsies of salivary gland adenomas found the
presence of tumor cells along the needle track immedi-
ately following aspiration with a 22-gauge needle, but
were not able to demonstrate increased tumor recurrence
at 5-year follow-up,12 further supporting the safety and
promoting the widespread adoption of fine-needle aspira-
tion in the evaluation and management of salivary
lesions. Ultrasound-guided core biopsy has more recently
emerged as an alternative to fine-needle aspiration cytol-
ogy.13,14 Whether improved diagnostic accuracy and
decreased rates of sample insufficiency compared with
fine-needle aspiration justify the increasingly invasive
procedure and potentially higher rate of complications
(including facial nerve damage, hemorrhage, tumor track
seeding, or capsule rupture) remains unanswered.15
Advantages of ultrasound-guided core biopsy compared
with fine-needle aspiration cytology
Ultrasound-guided core biopsy obtains a larger sample
size for analysis than fine-needle aspiration cytology,
which lowers the rate of sample inadequacy (estimated at
1.2% in ultrasound-guided core biopsy compared with
8.1% in fine-needle aspiration cytology). This is espe-
cially important at smaller medical centers where a cyto-
pathologist cannot be on hand for immediate specimen
assessment.16 Additionally, ultrasound-guided core biopsy
preserves the histologic architecture of specimens,
improving the accuracy of the diagnosis, and allowing
additional diagnoses (eg, capsular invasion) not possible
from fine-needle aspiration biopsy. Furthermore, a wider
array of immunohistochemical techniques can be con-
ducted from ultrasound-guided core biopsy samples than
from fine-needle aspiration biopsy samples. These factors
have led to substantial differences in reported diagnostic
accuracy between the 2 techniques. Recently published
meta-analyses have found that ultrasound-guided core bi-
opsy has an overall sensitivity of 0.92 (95% confidence
interval [CI], 0.77–0.98) and overall specificity 1.00
(95% CI, 0.76–1.00). This is compared with fine-needle
aspiration cytology, which has been found to have a sen-
sitivity of 0.96 (95% CI, 0.83–0.99) and specificity of
0.98 (95% CI, 0.67–1.00) for distinguishing neoplastic
from non-neoplastic lesions. These numbers fall substan-
tially, however, to sensitivity of 0.80 (95% CI, 0.76–0.83)
and specificity of 0.97 (95% CI, 0.96–0.98), when distin-
guishing if such neoplastic lesions are benign or
malignant.5,6
Another potential problem with fine-needle aspiration
is the variability (SD of sensitivity estimated at 18%) and
heterogeneity between different facilities, studies, and
countries. This variability was evident in recent studies
estimating the sensitivity when distinguishing benign
from malignant disease as low as 0.38 (95% CI,
0.13–0.63)17 and 58%.18 This stands in contrast to other
published sensitivity values of 73%19 and 87.8%.20 The
wide range of sensitivity values complicates standardiza-
tion of uniform recommendations regarding the utility of
fine-needle aspiration biopsy compared with ultrasound-
guided core biopsy and suggests that a positive diagnosis
by fine-needle aspiration cytology may be reliable,
although the high potential false-negative rate may
require confirmation of negative diagnosis via ultrasound-
guided core biopsy.5,6
Ultrasound-guided core biopsy has also improved diag-
nostic accuracy in specific cytological diagnoses includ-
ing pleomorphic adenoma,21 Warthin’s tumor,22 and lym-
phoma,23 which have traditionally been difficult to
diagnose via fine-needle aspiration biopsy alone. Further-
more, ultrasound-guided core biopsy may have increased
diagnostic utility over fine-needle aspiration biopsy when
diagnosing systemic disease such as sarcoidosis and
Sj€ogren’s syndrome.
Advantages of fine-needle aspiration cytology compared
with ultrasound-guided core biopsy
The most obvious and immediately evident advantages
to fine-needle aspiration cytology are that it is less pain-
ful and less frightening to the patient than ultrasound-
guided core biopsy. Additionally, ultrasound-guided core
biopsy requires local anesthesia and has been found to
have greater morbidity (with an overall rate of hematoma
estimated at 1.7%, although none required treatment).
The more concerning, latent, disadvantage to ultrasound-
guided core biopsy is the increased potential for seeding
malignant cells along the needle tract. Although cases of
tumor seeding have been reported for needles as small as
23 French gauge,24 anecdotal evidence and mechanism of
action suggest tumor seeding to be more common with
larger needles,25,26 meaning that ultrasound-guided core
biopsy (which uses a 16- to 18-gauge needle) may have
increased potential for tumor seeding and capsule rupture
compared with fine-needle aspiration cytology (which
uses a 20-gauge or smaller). At the current time, no stud-
ies have formally evaluated the relationship between nee-
dle diameter and tumor seeding in salivary gland lesions
or other, more general neoplasms.27 Furthermore, fine-
needle aspiration has a theoretical lower risk for facial
nerve injury, although proper identification of intraparotid
vessels on ultrasound minimize risk of facial nerve dam-
age during biopsy.9 A series of 53 patients undergoing
ultrasound-guided core biopsy showed no episodes of fa-
cial nerve palsy and no recurrence due to seeding of can-
cer at the needle tract during follow-up of 12.2 to 77.5
months (mean follow-up is 33.6 months).28 Other studies
advocating the safety and reliability of ultrasound-guided
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core biopsy were limited by a relatively brief follow-up
in which there was no tumor recurrence and only small
patient populations.9,13,29–34 Novoa and colleagues1 exam-
ined the issue of tumor seeding from ultrasound-guided
core biopsy in their review, finding no evidence based on
7 years of clinical follow-up in 438 lesions. Furthermore,
only 2 studies characterized tumor cell displacement fol-
lowing core biopsy, the first using scanning electron mi-
croscopy35 and the second with histologic examination of
excised needle tracts.36 These studies reported evidence
of tumor cell displacement following biopsy in 1 case of
a total of 145 lesions (0.2%), following biopsy of a ma-
lignant melanoma.1,36
Seeding of malignant cells in needle track:
clinical evidence
The risk of tumor-tract seeding varies dramatically as a
function of both tumor type and anatomic site. Although
needle-tract recurrences occur most commonly with pan-
creatic cancer, hepatocellular carcinoma, prostate cancer,
and mesothelioma, reports have identified cases for nearly
every tumor type including: (1) retinoblastoma,37 (2) lipo-
sarcoma,24 (3) thymoma,38 (4) breast cancer,39 (5) thyroid
cancer,40,41 and (6) CNS tumors.42 Because of this risk
and the assumed relationship between needle diameter
and seeding potential, certain biopsy techniques, includ-
ing: (1) use of a fine, noncutting needle, (2) sample under
suction, and (3) minimizing the number of passes that
should be maintained to minimize the potential risk for
tumor seeding.26
Initial studies on the safety of fine-needle aspiration for
biopsy of salivary gland adenomas identified the presence
of tumor cells along the needle-track immediately follow-
ing fine-needle aspiration (22-gauge needle), but did not
find an increased number of recurrences during the 5-year
follow-up.12 The presence of cells in the immediate inter-
val following biopsy highlights the risk for tumor seeding
of the needle track, although the lack of recurrence sug-
gests that salivary neoplasms (due to a combination of
number of cells dislodged, adhesiveness, presence of
stroma, and immunologic characteristics) are relatively
resistant to tumor seeding.43 Analysis of 11 patients who
had pleomorphic adenoma surgically excised following
ultrasound-guided core biopsy showed no cases of tumor
recurrence during the follow-up period, which ranged
from 28.9 to 76.5 months (mean, 48.6 months).28
Although tumor seeding for salivary gland lesions occurs
infrequently in both ultrasound-guided core biopsy and
fine-needle aspiration biopsy, there have been reported
cases of tumor seeding for both techniques.
The 2 earliest case reports of tumor seeding from sali-
vary biopsy both involved needles of similar diameter to
those typically used in ultrasound-guided core biopsy.7,8
Yamaguchi and colleagues7 reported of seeding a parotid
carcinoma along a Vim–Silverman needle (14- to 16-
gauge) tract, and advised excision of the biopsy site at
definitive surgery, whereas hypothesizing that biopsy with
a fine needle to be less likely to promote tumor seeding.
Two, more recent, cases (adenoid cystic carcinoma of the
submandibular gland and pleomorphic adenoma of the
parotid gland) have reported tumor seeding following
fine-needle aspiration cytology.44,45
Novoa and colleagues1 recently reviewed the clinical
efficacy and safety of ultrasound-guided core biopsy in
the work-up of head and neck lesions. Their meta-analysis
found a relatively small number of publications, which
were limited by: (1) a small number of patients, (2) a
short follow-up, and (3) a retrospective study design.
Review of 438 lesions with 7 years of clinical follow-up
found no evidence of tumor-cell seeding.
Evidence for seeding along the needle tract:
animal models
Despite infrequent recurrence of salivary tumors along
the needle tract in a clinical setting, animal models of sal-
ivary (as well as other types of tumors) highlight a mech-
anism where, at least the potential, for tumor tract seeding
still strongly exists.46 Animal studies have quantified a
high percentage of malignant cells following biopsy (83%
and 89%).12,47 Another study, in which biopsy needles
(23-gauge) were passed ‘‘through’’ the leg muscle of a
healthy mouse into a tumor-implanted mouse, demon-
strated that tumor seeding occurred between 65% and
83% of the healthy animals with a seeding quantity rang-
ing anywhere from 102 to 104 tumor cells per instance.
These animal models demonstrate that despite technical
protocol and precautions, the biopsy procedure commonly
spills tumor cells into the tissue surrounding the needle
tract. Clinical episodes of needle tract seeding remain rel-
atively infrequent (the largest study following fine-needle
abdominal biopsies in 11,700 patients estimated rate of
tumor seeding at 0.017%).11 Although the mechanism
behind tumor recurrence remains an area of active
research, the number of seeded cells and amount of
stroma seeded dictate the incidence of implantation and
growth.48 Because larger-bore needles, such as those used
in ultrasound-guided core biopsy, aspirate a greater num-
ber of neoplastic and stromal cells, needle diameter
should be minimized while maintaining diagnostic
accuracy.
Recurrence of pleomorphic adenoma: frequency and
time course
Pleomorphic adenoma is the most common salivary
gland neoplasm, accounting for between 50%49 and
70%50 of all salivary gland tumors. Recurrence of pleo-
morphic adenoma following superficial parotidectomy is
estimated between 1% and 3%.51,52 Whereas the majority
of initial recurrences occur within the first 5 to 10
years,53–56 recurrences have been reported up to 20 years
following resection.57 The average duration of recurrence
varies greatly in published reports, with Natvig and
Soberg,4 who followed patients for an average of 18 years
postoperatively, reporting a mean recurrence interval of
11.8 years postoperative, substantially longer than the 6.1
years reported by Niparko and colleagues,3 who followed
their patients for an average of 16.5 years postoperatively.
Furthermore, Fee and colleagues2 found that 16% of tu-
mor recurrences took place at least 10 years following
initial surgery. Another study by Stevens and Hobsley52
with a median of 4 years, showed no recurrences in 72
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patients following primary parotidectomy for pleomorphic
adenoma. Such apparent differences as a function of
study follow-up duration, highlights the necessity in study
design for adequate length of observation to detect
remote recurrence. Multiple authors recommend 20-year
follow-up in this patient group.4,53,58
A review of 17 pleomorphic adenoma resections with
either tumor spill or inadequate tumor resection, showed
a 24% recurrence,59 although there was no recurrence in
the subset of 6 patients receiving postoperative radiation.
When considering only parotidectomies (excluding the 3
enucleation procedures, all of which resulted in tumor re-
currence) the recurrence rate was found to be between
7% for the entire group and 13% for the cohort receiving
surgery with no postoperative radiation. This number, in
a population with known tumor spillage or inadequate
resection, compares with an overall recurrence rate of
<2% in all parotidectomies.51,52,58 Although microscopi-
cally positive margins following resection were linked to
increased tumor recurrence, tumor spill was not independ-
ently shown to be associated with an increased rate.59
Role of capsule rupture on tumor seeding
Another potential risk with the use of larger-diameter
needles in ultrasound-guided core biopsy is the breach of
the tumor capsule. Initial research suggested that risk of
recurrence of benign salivary gland pleomorphic adeno-
mas did not depend on capsule rupture, but on the pres-
ence of microscopic pseudopodia extending outside the
pseudocapsule.60 This contrasts with a more recent study,
which shows that tumor puncture and spillage are the
only variables to have an independent effect on the recur-
rence of pleomorphic adenomas. Natvig and Soberg4
found tumor recurrence of 8% following capsule rupture
compared with a baseline recurrence rate of 2.5%.
DISCUSSION
The potential for tumor spillage, capsule rupture, and
tumor recurrence is intuitively escalated as a function of
needle diameter and sample volume. Ultrasound-guided
core biopsy, therefore, potentially has an increased risk
profile compared with that of the accepted fine-needle
aspiration cytology technique. Despite this potential risk,
studies investigating rates of tumor recurrence as a func-
tion of needle diameter (and biopsy technique) are lack-
ing, not only for salivary gland lesions, but for all tumor
types. Although animal study models suggest that tumor
cells are spilled in the overwhelming majority of biopsy
procedures (estimated between 65% and 85%), these
spilled cells rarely lead to tumor recurrence, and is a
function of host immunity, number of cells, and the char-
acteristics of the tumor cell and local tissue (‘‘seed and
soil’’ hypothesis). Despite lower inherent tumorigenic
potential of salivary gland tumors (compared with pancre-
atic cancer, hepatocellular carcinoma, prostate cancer,
and mesothelioma), the amount of tumor cells spilled
should always be minimized. Roussel and Novet26 recom-
mend biopsy techniques, such as (1) use of a fine,
noncutting needle, (2) sample under suction, and (3) min-
imize the number of passes.
An alternative option in the work-up of salivary gland
tumors is to simply undergo parotidectomy with intrao-
perative frozen section (and no preoperative diagnostic
maneuvers). Although certainly a reasonable alternative
with the advantage of eliminating potential for preopera-
tive tumor-tract seeding or capsule rupture, preoperative
diagnosis allows for better counseling and planning for
additional procedures (such as neck dissection, possible
nerve sacrifice) in the setting of malignant tumors. It can
also be helpful to know if a particular tumor is metastatic
to the salivary gland (such as skin cancers, squamous cell
carcinoma, and melanoma) rather than a primary tumor.
The short time course of postoperative histologic con-
firmation compared with the long time course of tumor
recurrence, ensures that the benefits (increased diagnostic
accuracy and consistency, decreased rates of insuffi-
ciency) are readily apparent, whereas the potential draw-
backs (tumor seeding, tumor recurrence) are more latent.
Since widespread adoption of ultrasound-guided core
biopsy has emerged only within the last decade, and tu-
mor recurrence occurs in such small percentages of
patients (estimated between 1% and 3% following super-
ficial parotidectomy) and over such a long clinical win-
dow (reports as long as 20 years postoperatively), we
contend that current studies lack appropriate statistical
power and follow-up necessary to confirm the safety of
ultrasound-guided core biopsy. Further basic science
research into the mechanisms behind seeding and correla-
tion between needle diameter/biopsy technique and cell
spillage needed. Further clinical investigation of tumor
recurrence following both fine-needle aspiration cytology
and ultrasound-guided core biopsy are needed in large-
scale patient populations over a time course as long as 20
years before the safety of ultrasound-guided core biopsy
can be verified and widely accepted. Physicians should
weigh the relative advantages of each technique against
the supporting safety profile when determining optimal
work-up of salivary gland lesions.
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